State of the Science Summit on Hematologic Malignancies | Conference

Dr. Ghobadi on the Potential Development of CAR T Cells in Solid Tumors

November 8th 2018

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Dr. Dean on the Evolution of Treatment Approaches in MCL

November 3rd 2018

Robert Dean, MD, staff physician, Cleveland Clinic, discusses the evolution of treatment approaches in mantle cell lymphoma (MCL).

Kahl Highlights Frontline Considerations in Changing CLL Landscape

October 26th 2018

Brad Kahl, MD, discusses the rapidly evolving therapeutic landscape of CLL and the novel combinations on the horizon.

Reach of CAR T-Cell Therapy Poised to Extend in Oncology

October 26th 2018

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.

Treatment Regimens to Be Refined in Hodgkin Lymphoma

October 26th 2018

Nancy L. Bartlett, MD, discusses factors in treatment decisions for patients with advanced-stage Hodgkin lymphoma.

Dr. Bartlett on Treatment Regimens for Patients With Hodgkin Lymphoma

October 26th 2018

Nancy Bartlett, MD, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses treatment regimens for patients with Hodgkin lymphoma.

Dr. Kahl on the Impact of Venetoclax in Chronic Lymphocytic Leukemia

October 25th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the impact of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Uy on Therapy Selection in Acute Myeloid Leukemia

October 23rd 2018

Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).

Dr. Vij on the Optimal Induction Therapy in Multiple Myeloma

October 20th 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Dr. Oh on the Development of JAK Inhibitors in Myelofibrosis

October 20th 2018

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

Dr. Kahl on Ibrutinib in CLL

October 19th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Valent on MRD Negativity in Multiple Myeloma

October 11th 2018

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Dr. Carraway on Predisposition to Acute Myeloid Leukemia

October 11th 2018

Hetty Carraway, MD, oncologist, Cleveland Clinic, discusses predisposition to acute myeloid leukemia (AML).

Targeted Agents Beyond Ruxolitinib Necessary in Evolving MPN Paradigm

October 11th 2018

Aaron Gerds, MD, discusses the activity and drawbacks with current systemic agents in myeloproliferative neoplasms.

Combinations May Confer Benefit in MDS Management

October 11th 2018

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.

Zonder Addresses Unanswered Questions in Newly Diagnosed Myeloma

October 10th 2018

Jeffrey A. Zonder, MD, discusses triplet regimens in multiple myeloma and patient eligibility for clinical trials.

Expert Weighs Treatment Methods in Hodgkin Lymphoma

May 22nd 2018

Nilanjan Ghosh, MD, PhD, discusses the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.

Role of Checkpoint Inhibition in Most Hematologic Cancers Unclear, But Potential Remains

May 8th 2018

Saad Z. Usmani, MD, discusses the current state of immune checkpoint inhibitors in hematologic cancers, recent setbacks, and ongoing studies that could further shape the landscape.

Novel Agents Advance Acute Leukemia Treatment, But Challenges Remain

May 8th 2018

Michael R. Grunwald, MD, discusses new and emerging agents in acute myeloid leukemia and acute lymphoblastic leukemia, as well as sequencing and toxicity challenges with these treatments.

Expert Summarizes Strides in Relapsed Myeloma, Says More to Come

May 8th 2018

Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.